T cells in Nose of Older adults (TINO)

Identifying the underlying mechanisms and consequences of the loss of nasal T cells in vital and frail older individuals

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON24946

Enrollment

170

Registered

2021-10-18

Start date

2021-11-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory infections, Aging

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: • Healthy elderly (>65yrs) that are not frail (frailty score 1-3) • Frailty (frailty score =4) elderly (>65yrs) These will be consist of individuals without a history of recurrent respiratory infections or with >2 self-reported episodes of respiratory infection in the past year. • Healthy young (18-35yrs) adults

Exclusion criteria

Exclusion criteria: • Incompetence to provide informed consent prior or during study • Current smoker or >40 pack year history • History of severe nose bleedings • Diagnosed with asthma, COPD or chronic rhinosinusitis • Use of inhalation corticosteroids or antibiotics in the past 6 weeks • Current use of anti-coagulants (to prevent nosebleeds) • Respiratory tract infection or common cold in the past 2 weeks • Immunocompromised individuals (with primary immune deficiency or secondary immune deficiency) • Life expectancy <28 days in the opinion of study physician • Vaccination in the 2 months prior to study start A potential subject that is only excluded from participation based on a recent vaccination will be asked to re-participate 2 months post vaccination.

Design outcomes

Primary

Measure	Time frame
To compare nasal CD8+ T cell frequency between young adults and frail older adults.	—

Secondary

Measure	Time frame
1. In depth profiling of T cells in nose and blood of young adults and older adults with and without frailty. 2. Assess the stability of T cell populations and other immune populations over time. 3. Compare blood and nasal T cells between older adults with and without recurrent respiratory tract infections. 4. Compare other nasal and systemic immune populations and parameters between young adults, vital older adults and frail older adults (with or without recurrent infections). 5. Associate nasal and systemic factors (e.g. cytokines and metabolites) and with T cells. 6. Associate respiratory tract microbiota with T cells and other immune parameters. 7. Associate covariates, such as biological age, HLA type and sex with T cells and other immune parameters. 8. Assess the impact of acute respiratory tract infection on (antigen-specific) T cell populations and other immune parameters in nose and blood.	—

Measure

Time frame

1. In depth profiling of T cells in nose and blood of young adults and older adults with and without frailty. 2. Assess the stability of T cell populations and other immune populations over time. 3. Compare blood and nasal T cells between older adults with and without recurrent respiratory tract infections. 4. Compare other nasal and systemic immune populations and parameters between young adults, vital older adults and frail older adults (with or without recurrent infections). 5. Associate nasal and systemic factors (e.g. cytokines and metabolites) and with T cells. 6. Associate respiratory tract microbiota with T cells and other immune parameters. 7. Associate covariates, such as biological age, HLA type and sex with T cells and other immune parameters. 8. Assess the impact of acute respiratory tract infection on (antigen-specific) T cell populations and other immune parameters in nose and blood.

—

Contacts

Public ContactWesley Huisman

Leiden University Medical Center

w.huisman@lumc.nl31 71 526 1455

Outcome results